Bionano Genomics earnings missed by $0.03, revenue fell short of estimates

Bionano Genomics (NASDAQ: BNGO) released its third quarter results, revealing that earnings per share (EPS) fell short of expectations. The company reported an EPS of $-0.4500, $0.03 below the analyst consensus of $-0.4200. Additionally, revenue for the quarter was $8.28M, significantly lower than the estimated $8.75M. Looking ahead, Bionano Genomics predicts FY 2026 revenue to be between $31.0000M and $33.0000M, which is below the analyst consensus of $32.4700M.

The stock price of Bionano Genomics closed at $1.23, marking a 4.2400% increase over the last three months but a 23.1300% decline over the past 12 months. The company has experienced 1 positive and 0 negative EPS revisions in the past 90 days. Bionano Genomics is currently assessed as having a fair performance financial health score.

To view the stock's historical reactions to earnings and explore the company's financials, visit Investing.com's dedicated resource. For a comprehensive list of upcoming earnings reports, refer to Investing.com's earnings calendar.